Table of Contents
The following was submitted by Zoll:
ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, recently announced it has appointed Winchester resident Eric Knudsen as its new chief executive officer, effective April 1.
Knudsen will succeed Jon Rennert, who served as ZOLL’s CEO for the past 10 years and will assume a new role as Executive Chairman of ZOLL’s Board of Directors.
“As a global leader in medical technology, ZOLL is continually looking for ways to expand our business and reach more patients in need,” said Rennert. “Eric has played a unique role in developing our growth strategies and driving our expansion, and I am confident he will lead ZOLL to even greater growth and success.”
“I am honored to become ZOLL’s next CEO,” said Knudsen. “ZOLL has a long legacy of innovation and clinical excellence, and today our medical devices, software, and related services are used worldwide to diagnose and treat patients suffering from serious cardiopulmonary and respiratory conditions. We will continue to lead with our commitment to patients and customers and our passion for improving outcomes and helping save lives.”
Knudsen has nearly 30 years of experience in the medtech industry, with deep expertise in business development and corporate strategy. He led ZOLL's Corporate Development team for six years and was responsible for investing in strategic relationships and acquiring more than a dozen new technologies.
For the past four years, Knudsen was president of ZOLL Itamar, a division of ZOLL that is focused on the diagnosis of sleep disorders. Knudsen led the division through significant growth and a dramatic increase in profitability.
Prior to joining ZOLL in 2013, Knudsen held leadership positions in international sales, marketing, and manufacturing partnerships at Covidien (now Medtronic), Aspect Medical Systems, and LeMaitre Vascular. He has an MBA from the Thunderbird School of Global Management and a bachelor’s degree from Boston College.
Rennert was named CEO of ZOLL in 2016, after serving as President of the company’s largest business unit for eight years. Under Rennert’s leadership as CEO, ZOLL expanded its reach as a global leader in external defibrillation, pioneered novel solutions for patients with serious cardiopulmonary and respiratory conditions, and significantly broadened its portfolio of products.
